From SNPedia
rs351855, a SNP in the fibroblast growth factor receptor 4 (
FGFR4) gene, is also known as the Gly388Arg variant. The
rs351855(T) allele encodes the risk (Arg) allele.
The Arg form of this SNP is likely to cause a harder to treat version of node-positive breast cancer, including reducing the efficacy of Herceptin, based on a study of 372 patients.[PMID 16822847]
A study of ~500 Japanese prostate cancer patients found that individuals with a rs351855(T;T) genotype had a 2.2- and 1.9-fold increased risk of prostate cancer and benign prostate hyperplasia (BPH), and a 1.8-fold increased risk of metastatic prostate cancer compared to the (C;C) genotype.[PMID 18756523]
[PMID 18762813] ~1500 prostate cancer patients showed only a weak association between rs351855 and prostate-cancer specific mortality, and no evidence associating it with prostate cancer risk, disease aggressiveness, Gleason score, or stage.
- related to CANCER PROGRESSION AND TUMOR CELL MOTILITY according to omim 134935.0001
| ? | (C;C) (C;T) (T;T) |
|---|
 |
| PharmGKB | PA161822200 |
| Name | FGFR4:GLY388ARG, FGFR4:Arg388 |
| Annotation | This variant is associated with cancer progression and tumor cell motility. Patients carrying arg388 allele was associated with metastasis and poor prognosis in breast cancer and in colon cancer as well as poor clinical outcome for head and neck squamous cell carcinoma. possible association with sensitivity to cisplatin. It is associated with resistence to adjuvent systemic therapy in primary breast cancer. |
| Gene | FGFR4 |
| Featue | |
| Evidence | PubMed ID:11830541; PubMed ID:15197773; PubMed ID:16822847; PubMed ID:17084840; PubMed ID:18487077 |
| Drugs | cisplatin, cyclophosphamide, fluorouracil, methotrexate, tamoxifen |
| Diseases | Breast Neoplasms |
| Curation Level | Curated |
